Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 64.47 |
| Open | 64.43 |
| Bid | 64.01 x 1800 |
| Ask | 64.96 x 900 |
| Day's range | 63.90 - 64.80 |
| 52-week range | 57.19 - 74.12 |
| Volume | |
| Avg. volume | 9,408,023 |
| Market cap | 81.96B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 18.10 |
| EPS (TTM) | 3.58 |
| Earnings date | 27 Jul 2022 - 01 Aug 2022 |
| Forward dividend & yield | 2.92 (4.53%) |
| Ex-dividend date | 14 Jun 2022 |
| 1y target est | 69.30 |
- Zacks
The Zacks Analyst Blog Highlights JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical
JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.
- Zacks
Top Research Reports for JPMorgan, Gilead Sciences & CSX
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).
- Business Wire
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
FOSTER CITY, Calif., May 19, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at: https://www.fcaaids.org/inform/philanthropic-support-to-address-hiv-aids/, is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes 2020 funding data (the most recent year available) revealing
